Drug Trial Radar · NCT06178055
A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)
Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Apr 16, 2024
Primary completion
Mar 3, 2025
Study completion Nov 30, 2025
Sponsor
- Lead sponsor
- Kyoto Drug Discovery and Development Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Central retinal artery occlusion (CRAO) is an ophthalmologic emergency which leads to severe and permanent vision loss. There is no evidence-based therapy for CRAO. The objective of this GION study is to evaluate the efficacy and safety of KUS121 intravitreal (IVT) injection in participants with acute non-arteritic CRAO.
Conditions
- Central Retinal Artery Occlusion
Interventions
KUS121 high doseDrug
Participants will receive KUS121 high dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
KUS121 low doseDrug
Participants will receive KUS121 low dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
Sham procedureDrug
Participants will receive a sham procedure that mimics an intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of study eyes which achieve a gain of 15 ETDRS letters or more in BCVA at Week 12 compared to baselineTime frame: At baseline, Week 12
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
The Retina Partners
Encino, California
Salehi Retina Institute, Inc
Huntington Beach, California
Kaiser Permanente Oakland Med Ctr.
Oakland, California
Florida Retina Institute
Jacksonville, Florida
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Kresge Eye Institute/Wayne State University
Detroit, Michigan
NYEE Infirmary of Mount Sinai
New York, New York
UH Eye Institute
Cleveland, Ohio
Austin Retina Associates
Austin, Texas
Retina Consultants of Texas
San Antonio, Texas
Retina Consultants of Texas
The Woodlands, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.